Inozyme Pharma, Inc. announced the appointment of Deborah Wenkert, M.D. as senior vice president and chief medical officer, effective February 2, 2021. Dr. Wenkert, a leading pediatric rheumatologist with more than 20 years of experience in metabolic bone and genetic disorders, will direct Inozyme’s clinical development programs as well as scientific communications activities. She succeeds Pedro Huertas, M.D., Ph.D., who has stepped down from his position to pursue other interests. Dr. Wenkert previously served as chief medical officer of PreciThera, Inc., where she managed several early clinical development programs in rare bone diseases.